In the preliminary findings of a study conducted with the National Taiwan University Hospital, over 50% of sample cases were reclassified as HER2-expressing when 3D pathology was applied. HSINCHU, April 16, 2025 /PRNewswire/ -- JelloX Biotech Inc., a Taiwan-based startup at the forefront...
Read More Details
Finally We wish PressBee provided you with enough information of ( Greater Precision of HER2-Expressing Breast Cancer Treatment with 3D Pathology: New JelloX Research Collaboration )
Also on site :
- Security forces disperse Togo protesters demanding president’s resignation
- Are You Showering at the Wrong Time? Health Experts Weigh In
- Iconic TV Fitness Guru, 68, Posts Energetic Vacation Workout Video as Fans Say She's 'Smashing It'